Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04089358 |
Recruitment Status :
Recruiting
First Posted : September 13, 2019
Last Update Posted : May 23, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm | Other: Educational Intervention Device: FitBit Other: Goal Setting Other: Health Promotion and Education Other: Media Intervention Behavioral: Telephone-Based Intervention | Phase 3 |
PRIMARY OBJECTIVE:
I. To evaluate the effects of a multi-component physical activity intervention including a Fitbit, individualized goal setting, and a social media peer support group compared to the control condition (Fitbit only) on physical activity among adolescent and young adult survivors of childhood cancer (AYA survivors) who do not meet physical activity guidelines.
SECONDARY OBJECTIVES:
I. To evaluate the effects of a multi-component physical activity intervention including a Fitbit, individualized goal setting, and a social media peer support group compared to the control condition (Fitbit only) on biomarkers predictive of cardiometabolic health among adolescent and young adult survivors of childhood cancer (AYA survivors) who do not meet physical activity guidelines.
II. To evaluate the effects of a multi-component physical activity intervention including a Fitbit, individualized goal setting, and a social media peer support group compared to the control condition (Fitbit only) on health-related quality of life among adolescent and young adult survivors of childhood cancer (AYA survivors) who do not meet physical activity guidelines.
OUTLINE: Participants are randomized to 1 of 2 groups.
INTERVENTION GROUP: Participants receive educational materials about physical activity.
INTENSIVE PHASE (24 WEEKS): Participants wear a physical activity tracker (Fitbit) daily as well as receiving weekly reminders from study staff to wear it. They also receive goal setting sessions each week (by text, phone call, etc.) to set personalized step count goals using the Fitbit application (app). Lastly, participants receive an invitation to follow and post on an online social media peer support group (Instagram), where study staff provide encouraging advice and messages about physical activity 2-3 times per week, announce badges/awards every week, and moderate a forum to discuss physical activity and use of the Fitbit.
MAINTENANCE PHASE (24 WEEKS): Participants wear a Fitbit daily but do not receive reminders to wear it. They also set their own step count goals weekly and check in with study staff monthly for assistance with goal setting. Participants take the lead posting content on the Instagram account moderated by the study staff. Study staff only post once per week with general physical activity-related questions and provide no badges.
CONTROL GROUP: Participants receive educational materials about physical activity and wear a Fitbit daily for 48 weeks.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 384 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Investigator, Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors |
Actual Study Start Date : | October 26, 2020 |
Estimated Primary Completion Date : | December 30, 2025 |
Estimated Study Completion Date : | December 30, 2025 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Control Group (educational materials, Fitbit)
Participants receive educational materials about physical activity and wear a Fitbit daily for 48 weeks.
|
Other: Educational Intervention
Receive educational materials
Other Names:
Device: FitBit Wear a Fitbit |
Experimental: Intervention group (educational materials, goal set, Fitbit)
See outline
|
Other: Educational Intervention
Receive educational materials
Other Names:
Device: FitBit Wear a Fitbit Other: Goal Setting Set goals Other: Health Promotion and Education Receive text message about goal setting Other: Media Intervention Follow Instagram group Behavioral: Telephone-Based Intervention Receive phone call about goal setting |
- Change in minutes of moderate-to-vigorous physical activity (MVPA) per day from Baseline Evaluation [ Time Frame: 12 months ]Moderate-to-vigorous physical activity (MVPA) will be tracked using a wearable activity monitor (research-grade accelerometer) that counts how often (how many times) someone performs MVPA over a 7 day period. Total minutes above the moderate-intensity threshold will be divided by the number of valid days to obtain minutes of MVPA per day.
- Cardiopulmonary fitness [ Time Frame: 12 months ]Cardiopulmonary fitness is an objective biomarker of exercise capacity and will be assessed by the 2-Minute Step Test. During the 2-Minute Step Test, participants are asked to march in place as quickly as possible for 2 minutes. This test requires a stopwatch and a counter. Stopping, starting, and resting during the test are allowed as needed. Steps are counted.
- Body mass index (BMI) [ Time Frame: 12 months ]Participants will be measured for height and weight without shoes and wearing light clothes using a stadiometer or measuring tape and scale, respectively. BMI will be calculated as weight (kg) divided by height squared (m2). BMI will be examined as a potential covariate for the analysis of fitness as measured by the 2-Minute Step Test.
- Resting heart rate [ Time Frame: 12 months ]Resting heart rate will be taken using the Fitbit physical activity tracker heart rate monitor after the patient has been sitting upright with both feet on the floor for five minutes.
- Health-related quality of life (HRQOL) [ Time Frame: 12 months ]HRQOL will be measured with the Pediatric Quality of Life inventory (PedsQL) 4.0 Generic Core Scales (global functioning, physical functioning, and social functioning scales, specifically) and the 18-item PedsQL 4.0 Multidimensional Fatigue Scale, which encompasses three subscales: (1) general fatigue (6 items), (2) sleep/rest fatigue (6 items), and (3) cognitive fatigue (6 items).115-118 Questions refer to how much of a problem each item was during the past month. Items are reverse-scored and transformed to a scale from 0-100, in which higher scores indicate better HRQOL.
- Total cholesterol [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: total cholesterol.
- High density lipoprotein (HDL) [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: high density lipoprotein (HDL).
- Low density lipoprotein (LDL) [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: low density lipoprotein (LDL).
- Triglycerides [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: triglycerides.
- Glucose [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: glucose.
- Insulin [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: insulin.
- Hemoglobin A1c (HbA1c) [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: hemoglobin A1c (HbA1c).
- High sensitivity C-reactive protein (CRP) [ Time Frame: 12 months ]A dried blood sample will be collected on each participant after a minimum of an 8-hour fast. A total of 3 drops of blood will be collected by finger stick with a lancet. Samples will be tested for: high sensitivity C-reactive protein (CRP).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 20 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- First diagnosis of malignant neoplasm (International Classification of Diseases for Oncology [ICD-O] behavior code of "3") in first and continuous remission at the time of enrollment
-
Curative cancer treatment must have included chemotherapy (including cellular therapy) and/or radiation (including radioactive iodine)
- Note: Childrens Oncology Group (COG) therapeutic trial participation is not required
- All cancer treatment must have been completed within 3-36 calendar months prior to enrollment
- Patients must have a life expectancy of > 1 year
-
Self-report of < 420 minutes of moderate-to-vigorous physical activity per week as assessed via the study-specific Physical Activity Worksheet
- Note: See COG Study Web Page for the Godin-Shephard Leisure Time Physical Activity Questionnaire or link to online calculator
-
Ambulatory and no known medical contraindications to increasing physical activity
- Note: Patients with amputation, rotationplasty, or other prothesis are not automatically excluded as long as they are ambulatory and have no known medical contraindications to increasing physical activity and all other eligibility criteria are satisfied
- No known significant physical or cognitive impairment that would prevent use of the electronic devices used for the protocol intervention (e.g. Fitbit, smartphone, tablet, or computer)
-
Able to read and write English
- Note: For patients < 18 years, consenting parent/legal guardian does not have to be able to read and write English
-
All patients and/or their parents or legal guardians must sign a written informed consent
- Note: Informed consent may be obtained electronically/online if allowed by local site policy and Institutional Review Board (IRB)/Research Ethics Board (REB) of record
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Post-menarchal female patients who are pregnant or planning to become pregnant in the next year are excluded
- Note: Pregnancy status can be established by clinical history with patient. Post-menarchal female patients are eligible as long as they agree to use an effective contraceptive method (including abstinence) during study participation
-
Patients with previous hematopoietic stem cell transplant (HSCT) are excluded
- Note: Patients with previous autologous HSCT, chimeric antigen receptor T-cell (CAR T-cell) therapy, and other cellular cancer therapies can participate as long as all other eligibility criteria are satisfied

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04089358

Principal Investigator: | Nina S Kadan-Lottick | Children's Oncology Group |
Responsible Party: | Children's Oncology Group |
ClinicalTrials.gov Identifier: | NCT04089358 |
Other Study ID Numbers: |
ALTE2031 NCI-2020-01916 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) ALTE2031 ( Other Identifier: Children's Oncology Group ) COG-ALTE2031 ( Other Identifier: DCP ) ALTE2031 ( Other Identifier: CTEP ) U01CA246665 ( U.S. NIH Grant/Contract ) UG1CA189955 ( U.S. NIH Grant/Contract ) |
First Posted: | September 13, 2019 Key Record Dates |
Last Update Posted: | May 23, 2023 |
Last Verified: | April 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Neoplasms |